Message on Senate action sent to the House.
This bill reauthorizes and updates federal programs addressing opioid use disorder and related behavioral health needs through fiscal years 2026–2030. It increases funding authorizations, creates and expands grant programs (including a new fetal alcohol spectrum disorder program), mandates studies and reports, supports harm-reduction tools (e.g., fentanyl/xylazine test strips), requires cybersecurity measures for 9‑8‑8, and directs reviews or guidance on prescribing, drug scheduling, PDMP vendor choice, and health information technology.
Left emphasizes funding, harm reduction, and FASD supports
Relative to its intended legislative type, this bill is a well-structured substantive reauthorization package that makes numerous precise statutory amendments, establishes funding authorizations, and builds in multiple reporting and oversight requirements.
This bill reauthorizes and updates federal programs addressing opioid use disorder and related behavioral health needs through fiscal years 2026–2030.
It increases funding authorizations, creates and expands grant programs (including a new fetal alcohol spectrum disorder program), mandates studies and reports, supports harm-reduction tools (e.g., fentanyl/xylazine test strips), requires cybersecurity measures for 9‑8‑8, and directs reviews or guidance on prescribing, drug scheduling, PDMP vendor choice, and health information technology.
Reauthorizations of addiction‑focused programs with added funding and administrative tweaks historically clear Congress, though aggregate cost and a few sensitive provisions create moderate risk.
Relative to its intended legislative type, this bill is a well-structured substantive reauthorization package that makes numerous precise statutory amendments, establishes funding authorizations, and builds in multiple reporting and oversight requirements. It integrates directly with existing statutes and assigns responsibilities and timeframes to federal actors.
Left emphasizes funding, harm reduction, and FASD supports
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes funding, harm reduction, and FASD supports
Overall supportive.
The bill expands funding for prevention, treatment, recovery, workforce, and FASD services, and explicitly allows harm-reduction tools.
It strengthens 9‑8‑8 cybersecurity and promotes naloxone inclusivity, aligning with public-health and equity priorities.
Generally favorable but pragmatic.
The bill funds many evidence-based activities and administrative improvements, while adding reports and studies.
Concerns focus on measurable outcomes, privacy safeguards (e.g., wastewater surveillance), and fiscal accountability.
Skeptical.
While supporting some treatment and 9‑8‑8 protections, the persona worries about expanded federal spending, administrative growth, and perceived endorsement of harm‑enabling tools like test strips.
Prefers state control and limited new federal mandates.
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Still ahead
Reauthorizations of addiction‑focused programs with added funding and administrative tweaks historically clear Congress, though aggregate cost and a few sensitive provisions create moderate risk.
The House passed this bill. It now goes to the other chamber, and eventually to the President for signature.
The final vote on whether the bill becomes law (pending the other chamber and the President).
This amendment was rejected and will not be added to the bill.
An amendment modifies the text of a bill.
Left emphasizes funding, harm reduction, and FASD supports
Reauthorizations of addiction‑focused programs with added funding and administrative tweaks historically clear Congress, though aggregate c…
Relative to its intended legislative type, this bill is a well-structured substantive reauthorization package that makes numerous precise statutory amendments, establishes funding authorizations, and builds in multiple…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.